JPMorgan Chase & Co. initiated coverage on shares of Dechra Pharmaceuticals (LON:DPH) in a research note published on Monday morning. The brokerage issued an overweight rating and a GBX 3,000 ($39.20) price target on the stock.
Separately, HSBC cut their target price on shares of Dechra Pharmaceuticals from GBX 2,770 ($36.19) to GBX 2,700 ($35.28) and set a buy rating on the stock in a research note on Monday, March 11th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of GBX 2,711 ($35.42).
Shares of LON DPH opened at GBX 2,562 ($33.48) on Monday. The firm has a market cap of $2.63 billion and a P/E ratio of 105.87. Dechra Pharmaceuticals has a 12-month low of GBX 1,992 ($26.03) and a 12-month high of GBX 3,180 ($41.55). The company has a debt-to-equity ratio of 62.79, a quick ratio of 1.58 and a current ratio of 2.51.
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
Read More: What is the Rule of 72?
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.